Pricing norms outdated, says NPPA chief [Health, Governance]
- The price regulator in the pharmaceutical sector is of the opinion that the Drug Price Control Order (DPCO) is outdated and has to be amended.
- Such a step will help facilitate the National Pharmaceutical Pricing Authority (NPPA) look into subjects like biosimilars and medical devices.
- Currently, NPPA doesn’t have market data for 350 medicines that come under price control.
- DPCO also has to be amended in a way that it would help the drug price controller determine the price of coronary stents.
- NPPA doesn’t have a benchmark to work out the pricing mechanism for agents as done for other drugs.
- Foreign companies have pressed for higher prices for their “next generation” stents. The government is looking at amending the draft regulation for stents.